Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.49 |
| ▸ | FAP | Q12884 | 3/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14326434 | 0.96 | DPP4 (0.57) | DPP4HDAC2DPP8DPP9FAP | |
| SCHEMBL18461798 | 0.96 | DPP4 (0.57) | DPP4HDAC2DPP8DPP9FAP | |
| SCHEMBL14326148 | 0.96 | DPP4 (0.57) | DPP4HDAC2DPP8DPP9FAP | |
| Trifluoroacetic Acid SCHEMBL2500245 | 0.89 | HDAC2 (0.46) | DPP4HDAC2DPP8DPP9FAP | |
| SCHEMBL15075931 | 0.84 | DPP4 (0.49) | DPP4HDAC2DPP8DPP9FAP | |
| SCHEMBL3317269 | 0.84 | DPP4 (0.45) | DPP4HDAC2DPP8DPP9FAP | |
| SCHEMBL3830519 | 0.84 | DPP4 (0.49) | DPP4HDAC2DPP8DPP9FAP | |
| SCHEMBL26453442 | 0.84 | DPP4 (0.49) | DPP4HDAC2DPP8DPP9FAP | |
| SCHEMBL4456288 | 0.82 | HRH3 (0.52) | — | |
| SCHEMBL4449900 | 0.82 | HRH3 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297692-B2 | 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2007-11-20 | — | — | US | disclosed |
| US-20070004703-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-AVENTIS (FR) | 2007-01-04 | — | — | US | disclosed |
| US-7129240-B2 | 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2006-10-31 | — | — | US | disclosed |
| US-20040209938-A1 | Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI (FR) | 2004-10-21 | — | — | US | disclosed |
| US-6730695-B2 | TREATMENT OF HYPERTENSION, CENTRAL NERVOUS SYSTEM DISORDERS | SANOFI-SYNTHELABO (FR) | 2004-05-04 | — | — | US | disclosed |
| US-20030114683-A1 | Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors | SANOFI (FR) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114683-A1 | Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors | AVPR1B, AVPR1A, AVPR2 | DPP4 2745/4885HDAC2 2923/4885DPP8 3306/4885 |
| US-20040209938-A1 | Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them | AVPR2, AVPR1B, AVPR1A | DPP4 2282/4885HDAC2 2224/4885DPP8 3381/4885 |
| US-20070004703-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVPR1B, AVPR2, AVPR1A | DPP4 2689/4885HDAC2 2443/4885DPP8 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.